TB & Outbreaks Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB & Outbreaks Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Tuberculosis
Findings from University of Buenos Aires, Medical Department in tuberculosis reported
March 10th, 2009
" Human secretory leukocyte protease inhibitor (SLPI) displays bactericidal activity against pathogens such as Escherichia call and Streptococcus. Furthermore, it has been reported that murine SLPI shows potent antimycobacterial activity," scientists writing in the American Journal of Respiratory and Critical Care Medicine report. "The aim of the present study was to investigate whether human recombinant SLPI not only kills mycobacteria but also acts as a pattern recognition receptor for the host immune system. For the in vivo experiment, BALB/c mice were infected by intranasal instillation with Mycobacterium bovis BCG and viable BCG load in lung homogenates was...
Source: TB & Outbreaks Week (2009-03-10)
|
